Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy
- PMID: 23993766
- PMCID: PMC7110699
- DOI: 10.1016/j.ijid.2013.07.002
Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy
Abstract
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.
Keywords: Interferon; MERS-CoV; Ribavarin; SARS.
Copyright © 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
References
-
- AlBarrak A.M., Stephens G.M., Hewson R., Memish Z.A. Recovery from severe novel coronavirus infection. Saudi Med J. 2012;33:1265–1269. - PubMed
-
- CDC. Middle East Respiratory Syndrome. Available at: http://www.cdc.gov/coronavirus/mers/faq.html last accessed July 27, 2013.
-
- Assiri A., Al-Tawfi q J.A., Al-Rabeeah A.A. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013 published online July 26. http://dx.doi.org/10.1016/S1473-3099(13)70204-4. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous